Pathology and Tissue Core

医学博士的首要目标是：安西森癌症中心白血病孢子是改善治疗的 白血病患者。实现这一目标的一个基本组成部分是开展有重点的 涉及人体组织和血液标本的转化研究，允许调查生物学， 靶组织和正常组织，对靶组织和正常组织的治疗效果的评估，以及调节 相关的生物标志物。病理学和组织核心将收集、处理和维护人体组织 从患者中收集样本，并将这些组织分发给白血病孢子研究者。 病理学和组织核心具有以下目的： 1.开发和维护一个完整的细胞库，血清，DNA，RNA和来自血液的蛋白质 和从接受治疗的白血病和MDS患者获得的骨髓标本，或 在M.D.安德森癌症中心和其他参与SPORE相关研究的中心 临床试验在诊断时和治疗期间/治疗后采集和处理样本 与SPORE相关的临床方案，而在缓解或复发。核心将分发 组织标本提供给白血病孢子研究者进行分析，并提供 对白血病孢子项目中组织切片进行的研究进行解释。芯会 提供白血病孢子研究中所用样本的全面血液病理学表征 项目 2.维护一个包含详细临床和病理数据的全面、前瞻性交互式数据库 对于在M.D.接受治疗或评估的白血病和MDS患者，安德森癌症中心 以及参与SPORE相关临床试验的其他中心。 3.通过血液共享促进白血病间SPORE和白血病外SPORE合作 和骨髓资源。 在过去9年的资助中，核心已经完成了为所有白血病患者提供样本的使命。 SPORE项目，以及外部调查人员的要求。在当前供资期间（2008-2011年），我们 已经向SPORE研究人员以及白血病研究人员分发了10，278瓶材料 研究人员在孢子外。 相关性（参见说明）： 对白血病的研究取决于从患者身上获得的白血病样本的可用性。这些 白血病细胞被用来制造DNA、RNA和蛋白质，它们被用来鉴定白血病细胞的特征。 疾病和活细胞，用于测试白血病细胞如何响应刺激，或潜在的新的 治疗该核心提供了患者样本，这是理解和治疗白血病的关键。

The priinary aim of the M.D. Ancierson Cancer Center Leukemia SPORE is to improve the treatment of patients with leukemia. A fundamental component to meeting this objective is the conduct of focused translational research involving human tissue and blood specimens, allowing investigation of the biology of target and normal tissues, evaluation of treatment effects on both target and normal tissue, and modulation of, relevant biomarkers. The Pathology and Tissue Core will collect, process, and maintain human tissue specimens from patients and m\\ distribute these tissues to the Leukemia SPORE investigators. The Pathology and Tissue Core has the following aims: 1. Develop and maintain a repository of intact cells, serum, DNA, RNA, and protein derived from blood and bone marrow specimens obtained from patients with leukemia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. Samples are collected and processed at the time of diagnosis and during/after therapy with SPORE-associated clinical protocols, while in remission or at relapse. The Core will distribute tissue specimens to the Leukemia SPORE investigators for analysis and provide expertise in the interpretation of studies performed on tissue sections within Leukemia SPORE projects. The Core will provide comprehensive hematopathologic characterization of the samples used in Leukemia SPORE projects. 2. Maintain a comprehensive, prospective interactive database with detailed clinical and pathologic data for patients with leukeiTiia and MDS receiving care or evaluation at M.D. Anderson Cancer Center and other centers participating in SPORE-associated clinical trials. 3. Facilitate inter-leukemia SPORE and extra-leukemia SPORE collaborations through sharing of blood and marrow resources. Over the past 9 years of funding, the Core has fulfilled its mission of providing samples to all Leukemia SPORE projects, as well as outside investigators' requests. In the current funding period (2008-2011), we have distributed 10,278 vials of material to 95 requests to SPORE researchers as well as leukemia researchers outside the SPORE. RELEVANCE (See instructions): Research into leukemia depends on the availability of leukemic samples obtained from patients. These leukemic cells are used to make DNA, RNA and protein, which are used to identify the characteristics of the disease and viable cells which are used to test how leukemic cells respond to stimulation, or potential new therapies. This Core provides the patient samples that are key to understanding and curing leukemia.